Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities

Condition:   Multiple Primary Lung Cancers Interventions:   Drug: furmonertinib;   Drug: Placebo Sponsors:   Ruijin Hospital;   Fujian Medical University Union Hospital;   First Affiliated Hospital of Zhejiang University;   Second Affiliated Hospital, School of Medicine, Zhejiang University;   Tang-Du Hospital;   The First Affiliated Hospital of Nanchang University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials